Mainland Investors Chase Hong Kong Drug Stocks as Licensing Deals Gather Pace

Mainland Chinese investors have stepped up buying of Hong Kong listed pharmaceutical and biotech stocks, riding a renewed wave of overseas licensing agreements that is reshaping how China’s drug developers access global markets. The shift highlights growing confidence in innovative drug makers at